homepage-top-section

German pharmaceutical firm Boehringer Ingelheim has acquired Abexxa Biologics to expand its research efforts in cancer immunology and novel immunotherapeutic approaches. The financial details of the transaction were

Pfizer and its partner BioNTech have announced positive topline results from a pivotal trial of their Covid-19 vaccine in children aged 5 to 11 years. The Phase II/III

Spanish healthcare firm Grifols has agreed to acquire 100% stake in Tiancheng (Germany) Pharmaceutical from Tiancheng International Investment for $1.289bn (€1.1bn). Tiancheng Pharmaceutical owns 89.88% of Biotest ordinary

Health Canada has granted full approval to Moderna’s Spikevax and Pfizer-BioNTech’s Comirnaty Covid-19 vaccines for use in individuals aged 12 years and above. The regulator originally authorised Moderna’s

Eli Lilly and Company has announced that the US government is set to purchase additional doses of its neutralising antibody therapy, etesevimab, to treat Covid-19. Under the terms

Sanofi has completed the acquisition of messenger RNA (mRNA) therapies firm Translate Bio to expedite the use mRNA technology for the development of treatments and vaccines. The latest move

US-based biopharmaceutical firm AzurRx BioPharma has agreed to acquire clinical-stage biotechnology company First Wave Bio in a stock-and-cash deal valued at $229m. First Wave Bio is focussing on

The UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has approved Amgen’s sotorasib (Lumakras) to treat patients with specific non-small cell lung cancer with KRAS G12C mutation. To be

EnGeneIC has started dosing in Phase I clinical trial of the world’s first nanocellular technology-based anti-Covid-19 vaccine in healthy adults. Referred to as EnGeneIC Dream Vector (EDV), the